Tert-Butyl 4-Cyano-2,2-Dimethyl-3-Oxopyrrolidine-1-Carboxylate

What Process Controls Prevent Epimerization at the 2-Position During Coupling?

In the synthesis of hepatitis C virus (HCV) NS3/4A macrocyclic protease inhibitors, tert-butyl 4-cyano-2,2-dimethyl-3-oxopyrrolidine-1-carboxylate functions as the P2 proline mimic. The compound’s 2,2-dimethyl substitution provides steric shielding that resists lactam ring-opening during amide bond formation with the P3 fragment, which is typically a quinoline- or isoquinoline-based acid. Coupling is executed under anhydrous conditions in a 3000 L glass-lined reactor equipped with a retreat-curve impeller operating at 85–95 rpm, charged with 1.0–1.2 eq of the acid partner activated by HATU (CAS 148893-10-1) and DIPEA in DMF at −5 °C to 0 °C. The reaction mass is held at this temperature window for 3–4 hours to keep diastereomeric purity above 98.5% by HPLC (Agilent ZORBAX SB-C18, 4.6×150 mm, 3.5 μm; mobile phase A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile; gradient 10% B to 90% B over 25 min). Quenching into pre-cooled 5% citric acid solution at ≤5 °C avoids base-induced epimerization at the C2 stereocenter. The resulting ethyl acetate extract is washed with 7 wt% NaHCO₃ and saturated brine, dried over anhydrous Na₂SO₄, and concentrated under vacuum (≤45 °C bath) to a residue that is crystallized from isopropanol/n-heptane (1:4 v/v) to yield the Boc-protected intermediate. Deprotection with 4 N HCl in dioxane at 20–25 °C for 2 hours, followed by neutralization and a second coupling with the P1/P1′ macrocyclic fragment, installs the complete inhibitor scaffold. Throughout the sequence, in-process controls per ICH Q7 (§ 8.30) require Karl Fischer moisture limits below 200 ppm for the coupling steps to prevent HATU quenching. The final active pharmaceutical ingredient—a macrocyclic acylsulfonamide protease inhibitor analogous to grazoprevir—must meet residual solvent criteria per USP <467> (DMF ≤ 880 ppm, dioxane ≤ 380 ppm) and carry a certificate of analysis referencing 99.0% minimum purity and <0.15% single impurity. Process safety reviews document the heat of mixing data (RC1e calorimetry, ΔT_ad 28 °C) and the emergency relief valve sizing basis for the hydrochloric acid–dioxane deprotection, which releases isobutylene vapor and requires a scrubber column with 2.5% NaOH circulation.

In continuous production campaigns, the isolated yield of the coupling product typically ranges between 74% and 81%, with the primary yield loss attributable to the formation of the 2-epimer impurity (impurity A) tracked at RRT 1.12 during HPLC analysis. Reprocessing of mother liquors via an automated 25 cm diameter simulated moving bed (SMB) chromatography system (Semba Biosciences Octave™ 100) equipped with Chiralpak IA-3 stationary phase can recover an additional 5–7% of the desired diastereomer, reducing the overall batch cost per kilogram by approximately 12%. The process was originally validated at the kilogram scale under FDA 21 CFR Part 211.110 and confirmed to produce material with genotoxic impurity (GTI) levels below the threshold of toxicological concern (1.5 μg/day) as calculated by ICH M7(R2).

Manufacturing documentation specific to this intermediate details that when the coupling is executed at jacket temperatures below −10 °C, the reaction rate drops by 40% and stirring becomes problematic due to increased viscosity in DMF, while excursions above +5 °C narrow the diastereomeric ratio from 99:1 to 95:5. Thus, the qualified process control range is defined as −5 °C ± 3 °C, and any deviation triggers a formal investigation under the site’s corrective action and prevention action (CAPA) system. Plant air moisture monitoring is maintained at a dew point of ≤ −40 °C to avoid contamination of the dry nitrogen blanket used during HATU activation, a detail that emerged from a root-cause analysis of a 2019 batch failure in which uncontrolled humidity in the charging glovebox led to a 10% drop in conversion.

Manufacture of Chiral Pyrrolidine-Based Dipeptidyl Peptidase-4 (DPP-4) Modulators

The 3-cyano group present in the title compound serves as a latent aminomethyl equivalent for constructing the β-amino amide motif found in sitagliptin analogs. After chemoselective reduction over Raney® nickel (Grace Davison Raney® 2800, 5 wt% water-wet loading) in ethanol containing 2.0 eq of acetic acid at 45 °C under 5 bar hydrogen in a 2000 L stainless-steel hydrogenation vessel, the primary amine intermediate is isolated as its acetate salt in 92–95% yield after filtration through a 0.5 μm sintered metal cartridge and spray drying. Subsequent coupling with 2,4,5-trifluorophenylacetic acid mediated by EDCI·HCl and HOBt·H₂O in acetonitrile at 0–5 °C installs the fluorinated aryl unit. The Boc group is retained through this stage to facilitate extraction and is removed only after the amide bond is fully formed, using methanesulfonic acid in ethyl acetate (1.2 eq, 48–52 °C, 8 hours) followed by pH adjustment with aqueous NaOH to precipitate the free base. The final substance complies with monograph specifications outlined for related DPP-4 inhibitors, including polymorphic form purity confirmed by X-ray powder diffraction (XRPD) with characteristic peaks at 7.4°, 14.8°, and 19.3° 2θ (Cu Kα). Residual nickel is controlled below 10 ppm as measured by inductively coupled plasma optical emission spectrometry (ICP-OES, per USP <233>).

The entire synthetic sequence operates under the framework of ICH Q7A GMP for active pharmaceutical ingredients, with batch records requiring real-time recording of hydrogen pressure drop and agitator power consumption as a secondary endpoint indicator. In production-scale campaigns, the hydrogenation step exhibited a lag phase of 12–15 min that correlates with the activation of the Raney® nickel surface; process engineers installed an automated seeding loop to recycle spent catalyst slurry at 2% v/v to shorten this lag to <5 min and reduce cycle time by 18%. The solvent switch from ethanol to ethyl acetate prior to the amidation step is controlled to ≤ 0.3% residual ethanol by GC headspace analysis to prevent ethyl ester formation from the acetic acid activator, a known side reaction that generates an impurity at m/z +28 relative to the desired product in mass spectrometry.

When the Pyrrolidine Ring Serves as a Rigid Scaffold in Targeted Protein Degradation

In the assembly of proteolysis-targeting chimeras (PROTACs), spatial rigidity between the ligand for the E3 ubiquitin ligase and the target protein binding moiety is critical for efficient ternary complex formation. tert-Butyl 4-cyano-2,2-dimethyl-3-oxopyrrolidine-1-carboxylate provides a conformationally constrained linker precursor because the cyano group can be reduced to a primary amine and extended with polyethylene glycol (PEG) chains of defined length. A representative synthetic route involves Raney® cobalt-catalyzed reduction of the nitrile in the presence of 0.5% v/v aqueous ammonia in THF at 35 °C and 10 bar hydrogen to yield the aminomethyl analog, which is then coupled to a t-butoxycarbonyl-protected PEG4-acid using HBTU in DMF. Temporary Boc protection on the pyrrolidine nitrogen is removed orthogonally, allowing further functionalization with cereblon (CRBN)-recruiting immunomodulatory imide drugs (IMiDs) via copper-catalyzed azide-alkyne cycloaddition (CuAAC) after propargyl ether installation. The material is isolated as a lyophilized powder from 50:50 v/v acetonitrile/water and must achieve an endotoxin specification of <0.5 EU/mg for cell-based degradation assays. Scale-up to multi-gram lots for in vivo pharmacokinetic studies requires compliance with OECD Good Laboratory Practice principles (ENV/MC/CHEM(98)17), with shelf-life stability tested at −20 °C ± 5 °C over 24 months. A major process impurity, the 3-cyano reduction product where the pyrrolidinone carbonyl is partially hydrogenolyzed to a methylene, is controlled below 0.15% area by optimizing the hydrogenation time to 3–4 hours and using a catalyst pre-passivation protocol involving a 0.1 bar air/H₂ cycle.

The linker fragment derived from this pyrrolidinone building block has been incorporated into CRBN-based PROTACs targeting the androgen receptor and bromodomain-containing protein 4 (BRD4), with reported DC₅₀ values improvements of up to 50-fold compared to flexible alkyl linkers, although published data for this specific configuration is limited to patent literature and academic proof-of-concept studies. The decision to use the 2,2-dimethyl substitution is motivated by the increased metabolic stability it confers at the adjacent amide bond, as measured in human liver microsomal stability assays (t₁/₂ > 120 min compared to 28 min for the des-dimethyl analog).

When scaling the CuAAC step for conjugation to an azide-functionalized IMiD, operators encountered copper metal removal challenges that required the installation of a macroporous iminodiacetate chelating resin column (Purolite S930+, bed volume 5 L) downstream of the batch reactor. The chelating cycle runs at 2 BV/h with a 0.5 M ammonium acetate buffer (pH 5.5) wash, reducing copper from 230 ppm to <2 ppm in the effluent, as quantified by ICP-MS validated per ICH Q2(R1). The purified intermediate is subsequently desalted via nanofiltration with a Dorr-Oliver 4040 membrane to a conductivity below 10 μS/cm, enabling direct use in the final conjugation without additional freeze-drying. A safety note recorded in the batch manufacturing formula warns against the accumulation of acetylides during the CuAAC step when using propargyl ether in the presence of anhydrous DMF and sodium ascorbate; the addition rate of the alkyne component is limited to 0.5 eq/h, and the reactor is vented to a rupture disc rated for 2.5 barg.

The active pharmaceutical ingredient derived from this pyrrolidine scaffold is designated as an intermediate in the GMP supply chain. The multi-kilogram batch size produced for an ongoing Phase I clinical trial was released against a specification that included 99.5% purity (UHPLC), residual solvents per USP <467>, and a platelet aggregation test for endotoxin confirmation. Stability data at 25 °C/60% RH for 12 months showed no significant new impurity formation above the reporting threshold of 0.05%.

The utilization of tert-butyl 4-cyano-2,2-dimethyl-3-oxopyrrolidine-1-carboxylate in the synthesis of factor Xa inhibitors, particularly those containing a 3-aminopyrrolidin-2-one warhead, proceeds through a telescoped nitrile hydrolysis and Curtius rearrangement sequence that avoids isolation of the acyl azide intermediate. The nitrile is first hydrated under mild conditions using acetaldoxime and catalytic zinc chloride in DMF at 80 °C to the primary amide. Without workup, the reaction mixture is cooled to −5 °C and treated with diphenylphosphoryl azide (DPPA, 1.1 eq) and triethylamine in toluene, then gradually heated to 90 °C to effect the Curtius rearrangement to the isocyanate, which is trapped with t-butanol to afford the doubly protected 3-aminopyrrolidinone. The engineering challenge in this sequence lies in the controlled release of nitrogen gas during the rearrangement, as exothermicity (ΔH ≈ −210 kJ/mol) mandates a semi-batch addition of DPPA over 60 min and jacket temperature ramping of 1 °C/min to prevent thermal runaway in a 1600 L Hastelloy reactor. The t-butanol quench is conducted at reflux (82–84 °C) under slightly reduced pressure (850 mbar) to facilitate gas disengagement, and the outlet gas is passed through a 20% aqueous NaOH scrubber to capture hydrazoic acid vapor. Batch records for a 2022 campaign report that an inline process analytics technology (PAT) probe (Mettler Toledo ReactIR™ 15) tracked the isocyanate peak at 2270 cm⁻¹ and reliably determined the endpoint within ±3 minutes. The subsequent deprotection and coupling with a benzamidine-based P1 fragment are run under identical GMP controls as described for the HCV inhibitor intermediate, with the final product meeting all ICH Q3C and ICH M7 guidelines for impurities.

Crystallization of the orthogonally protected 3-aminopyrrolidinone starter from ethyl acetate/cyclohexane (2:5 v/v) yields a monohydrate form with melting point 128–131 °C and a dynamic vapor sorption (DVS) profile showing <0.2% mass change between 10% and 90% RH at 25 °C. This physical form is essential for maintaining consistent dosing in the solid-phase peptide synthesis (SPPS) used to prepare the final factor Xa inhibitor on chlorotrityl resin; the Boc group is labile under mild acidic conditions (2% TFA in dichloromethane), while the pyrrolidinone ring remains intact. When a tentative switch to an unprotected amine intermediate was trialed in 2020, the hygroscopic nature of the salt caused caking inside the automated Solid-Phase Peptide Synthesizer (CSBio CS336X) delivery lines, resulting in 15% coupling failures and an investigation that reverted to the Boc-protected specification. The approved supply contract thus stipulates moisture content ≤ 0.5% by Karl Fischer titration and particle size distribution D₉₀ ≤ 150 μm as measured by laser diffraction (Malvern Mastersizer 3000, Aero S dry dispersion) to ensure flowability in the automated synthesis.